20 min
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents PeerVoice Clinical Pharmacology Video
-
- Science
Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.
Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.
20 min